Erschienen in:
05.01.2021 | Original Article
Variation in management of post-operative atrial fibrillation (POAF) after thoracic surgery
verfasst von:
Heidi Oi-Yee Li, Heather A. Smith, Olivier Brandts-Longtin, Donna E. Maziak, Sebastien Gilbert, Paul Villeneuve, Sudhir Sundaresan, Andrew J. E. Seely
Erschienen in:
General Thoracic and Cardiovascular Surgery
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Abstract
Objectives
New-onset post-operative atrial fibrillation (POAF) is a frequent adverse event following major thoracic surgery and is associated with increased risk of perioperative morbidity, length of stay and stroke. It is managed initially with rate and rhythm control therapy; however, optimal duration and the need for anticoagulation are poorly understood. This study aims to assess practice variation regarding POAF management and duration.
Methods
This retrospective, single-center cohort study included patients who underwent major thoracic surgery and developed POAF between 2008 and 2017, managed with rate and rhythm control therapy alone. Demographic, clinical, and surgical variables/outcomes, POAF management, and incidence of POAF recurrence in the 30-day post-operative period were collected. Chi-square and T-tests determined significance.
Results
Of 2054 patients undergoing thoracic surgery, 155 (75%) patients developed POAF. Different rate and rhythm control agents were used, most commonly metoprolol. 107 (69%) continued rate and rhythm control therapy upon hospital discharge for a mean of 56 days. Among the 48 patients with discontinuation of rate and rhythm control therapy on discharge, none demonstrated recurrence of POAF; in contrast to 3 of 107 patients who continued on therapy. Among patients with CHA2DS2-VASc score ≥ 2, 15% were prescribed anticoagulation on discharge.
Conclusions
Use of rate and rhythm control therapy and anticoagulation for POAF is significantly varied in practice. Many patients are not continued on rate and rhythm control after hospital discharge, which does not appear to impact risk of POAF recurrence. Further research to inform guidelines for POAF management, including therapy duration and indications for anticoagulation is warranted.